Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral Hepatitis

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real‐life study

“…In the STIly trial, SVR was 96% in cirrhotic patients treated with SOF plus SMV without RBV . In a study by Aghemo et al., in patients with compensated cirrhosis and treated with a combination of SOF plus SIM with or without RBV, SVR was 93%. Similarly, in a study of Salomoni et al., SVR was 93.6% in cirrhotic patients treated with SOF plus SMV with or without RBV.…”

Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India

“…Real world experiences have shown high SVR 12 rates (91-98%) in patients treated with SOF/LDV with or without RBV in patients with genotype 1, including patients with cirrhosis and those who were treatment experienced. [9][10][11][12][13][14][15][16][17][18] However, most of these studies are from the developed countries like United States, United Kingdom, Italy, Spain and Germany. [9][10][11][12][13][14][15][16][17][18] There are no real world studies from the Asian subcontinent and developing countries like India.…”

Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy

“…Detailed phylogeographic analyses are particularly pertinent for clinically relevant lineages. Due to the rapid evolution of HCV treatments that achieve high viral cure rates, the regimen simeprevir with sofosbuvir, largely used as first-line treatment so far in Europe and in Italy [ 18 , 19 ], has recently been categorized as suboptimal for HCV1a infected patients [ 20 ]. Nonetheless, second-line NS5A inhibitor-based regimens can still be considered when the absence of relevant RAVs is confirmed [ 21 ].…”